Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Almstead Neil Gregory	2. Issuer Name and Ticker or Trading Symbol PTC THERAPEUTICS, INC. [ PTCT ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) EVP Research Pharma Ops & Tech
(Last) (First) (Middle) C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT	3. Date of Earliest Transaction (MM/DD/YYYY) 6/19/2018
(Street) SOUTH PLAINFIELD, NJ 07080 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	6/19/2018		M ⁽¹⁾		20000	A	$10.85	37154	D
Common Stock	6/19/2018		S ⁽¹⁾		8000	D	$48.09 ⁽²⁾	29154	D
Common Stock	6/19/2018		S ⁽¹⁾		12000	D	$48.46 ⁽³⁾	17154	D
Common Stock								5125	I	By spouse

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right To Buy)	$10.85	6/19/2018		M ⁽¹⁾			20000	⁽⁴⁾	5/15/2023	Common Stock	20000.0	$10.85	46898	D
Stock Option (Right To Buy)	$451.2							⁽⁴⁾	5/15/2019	Common Stock	200.0		200	D
Stock Option (Right To Buy)	$1149.6							⁽⁴⁾	2/2/2020	Common Stock	200.0		200	D
Stock Option (Right To Buy)	$490.8							⁽⁴⁾	4/27/2021	Common Stock	216.0		216	D
Stock Option (Right To Buy)	$218.4							⁽⁴⁾	1/10/2022	Common Stock	166.0		166	D
Stock Option (Right To Buy)	$10.85							⁽⁴⁾	5/15/2023	Common Stock	3102.0		3102	D
Stock Option (Right To Buy)	$27.05							⁽⁴⁾	1/27/2024	Common Stock	40000.0		40000	D
Stock Option (Right To Buy)	$51.0							⁽⁵⁾	1/1/2025	Common Stock	69550.0		69550	D
Stock Option (Right To Buy)	$30.86							⁽⁶⁾	1/3/2026	Common Stock	55000.0		55000	D
Stock Option (Right To Buy)	$11.23							⁽⁷⁾	1/2/2027	Common Stock	35000.0		35000	D
Stock Option (Right To Buy)	$18.01							⁽⁸⁾	1/2/2028	Common Stock	70000.0		70000	D
Stock Option (Right To Buy)	$508.8							⁽⁴⁾	10/7/2019	Common Stock	12.0		12	I	By spouse
Stock Option (Right To Buy)	$1149.6							⁽⁴⁾	2/2/2020	Common Stock	1.0		1	I	By spouse
Stock Option (Right To Buy)	$490.8							⁽⁴⁾	4/27/2021	Common Stock	7.0		7	I	By spouse
Stock Option (Right To Buy)	$218.4							⁽⁴⁾	1/10/2022	Common Stock	7.0		7	I	By spouse
Stock Option (Right To Buy)	$27.05							⁽⁴⁾	1/27/2024	Common Stock	1300.0		1300	I	By spouse
Stock Option (Right To Buy)	$51.0							⁽⁵⁾	1/1/2025	Common Stock	2060.0		2060	I	By spouse

Explanation of Responses:
(1)	The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan.
(2)	This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.58 to $48.37 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
(3)	This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.38 to $48.81 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
(4)	Currently exercisable.
(5)	This option was granted on January 2, 2015, and vests over four years, with 25% of the shares underlying the option vesting on January 1, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2016.
(6)	This option was granted on January 4, 2016, and vests over four years, with 25% of the shares underlying the option vesting on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
(7)	This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
(8)	This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Almstead Neil Gregory C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD, NJ 07080			EVP Research Pharma Ops & Tech

Signatures
/s/ Avraham S. Adler, attorney-in-fact		6/21/2018
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.